On the occasion of the tenth anniversary of the Innovative Medicines Initiative (IMI), Luxinnovation interviewed Prof Dr Reinhard Schneider, Head of ELIXIR-LU. The interview focused on the involvement of ELIXIR-LU and of the Bioinformatics Core of the Luxembourg Centre for Systems Biomedicine (LCSB) in IMI projects. It highlights the expertise of the team in data curation, integration and visual analytics, and details the role of the Luxembourg Node in projects such as eTRIKS, AETIONOMY and the soon to be launched FAIRPlus consortium. The full article is available on Luxinnovation website.
Prof Dr Schneider will be one of the speakers at the international conference and networking event that will take place in Luxembourg on 14 December 2018 to celebrate the first 10 years of IMI funding for medical breakthrough. More information about the event on the event webpage.
The article is part of a series about the Innovative Medicines Initiative (IMI) a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need. IMI is the world’s biggest public-private partnership in the life sciences.Go back to the news